VERAXA Biotech AG (NASDAQ: VRXA) announced new in vitro proof-of-concept data supporting its novel BiTAC-ADC technology platform, which is designed to improve precision in cancer treatment through tumor-restricted activation of therapeutic agents. The company reported that BiTAC-ADCs demonstrated the ability to distinguish between breast cancer and healthy cells and achieved dose-dependent killing of 3D tumor cell spheroids while minimizing toxicity through the use of separately delivered, systemically inactive precursor components.
VERAXA said the findings further validate the potential of its BiTAC-ADC platform and complement its BiTAC-TCE technology, providing the company with two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both platforms at the BIO International Convention in San Diego from June 22-25, 2026. To view the full press release, visit https://ibn.fm/QiPhH.
The BiTAC-ADC platform leverages a unique approach that uses two separately delivered components that combine selectively at the tumor site, reducing systemic toxicity compared to traditional ADCs. This proof-of-concept data marks a significant milestone for VERAXA, as it advances toward clinical development. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
VERAXA is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond.
For more information about VERAXA and its latest news, visit the company's newsroom at http://ibn.fm/VRXA.
